KELI Therapeutics
offers cells from the placenta (mesenchymal stromal cells, epithelial cells, trophoblasts and NK-cells), Umbilical cord (mesenchymal stromal cells) and cartilage (healthy & osteoarthritis chondrocytes) in R&D quality as well as in GMP quality. Besides cells and concerning media they also offer exosomes derived from the mentioned cells.
Besides the standard products, KELI Therapeutics is flexible to customizations (e.g. cell isolation using FBS or hPL; expansion in 2D or 3D, number of cells/vial and more).
Applications
- Drug Discovery: Enhance the discovery and development of new therapeutic compounds with high-quality human cells.
- Disease Modeling: Utilize accurate cellular models to understand better and treat various human diseases.
- Regenerative Medicine: Facilitate the advancement of cell-based therapies for tissue repair and regeneration.
- Toxicology Studies: Evaluate the safety and efficacy of new drugs and chemicals using reliable human cell models.
Benefits
- Comprehensive Cell Offerings: Access a wide range of human cells, including mesenchymal stromal cells, epithelial cells, trophoblasts, NK-cells from placenta, umbilical cord-derived mesenchymal stem cells, and chondrocytes from cartilage.
- Customization Flexibility: Tailor cell isolation and expansion processes to meet specific research needs, including options for 2D or 3D expansion, FBS or hPL usage, and varying cell quantities per vial.
- High-Quality Standards: Obtain cells in both R&D and GMP quality, ensuring they meet rigorous standards for various research applications.
- Exosome Products: Benefit from exosomes derived from the same high-quality cell sources for advanced research purposes.
Frequently Asked Questions
- What types of cells does KELI Therapeutics offer?
KELI Therapeutics provides a variety of human cells including those derived from the placenta, umbilical cord, and cartilage. These include mesenchymal stromal cells, epithelial cells, trophoblasts, NK-cells, and chondrocytes. - How can I customize my cell order with KELI Therapeutics?
You can customize your order by specifying preferences for cell isolation methods (e.g., FBS or hPL), expansion techniques (2D or 3D), and the number of cells per vial to suit your research requirements.
References
Cartilage Research
- Osteochondral repair and electromechanical evaluation of custom 3D scaffold microstructured by direct laser writing lithography. Cartilage. December 2021.
Link to publication - Clinical outcome after treatment of single and multiple cartilage defects by autologous matrix-induced chondrogenesis: research article. Journal of Orthopaedic Surgery. May-August 2019.
Link to publication - Customization of direct laser lithography-based 3D scaffolds for optimized in vivo outcome. Applied Surface Science. September 2019.
Link to publication - Fabrication of 3D micro-structured scaffolds by direct laser writing in pre-polymers for in vitro and in vivo studies. Frontiers in ultrafast optics: Biomedical, Scientific, and Industrial Applications XVII. February 2017. Link to publication
- Characterization of tissue engineered cartilage products: recent developments in advanced therapy. Pharmacological Research. November 2016.
Link to publication - Clinical outcome after treatment of characterised cartilage defects by autologous matrix-induced chondrogenesis in active patients. Osteoarthritis and Cartilage. April 2016. Link to publication
- Preclinical study of SZ2080 material 3D microstructured scaffolds for cartilage tissue engineering made by femtosecond direct laser writing lithography. Biofabrication. March 2015. Link to publication
Mesenchymal Stromal Cell Research
- Methods and criteria for validating the multimodal functions of perinatal derivatives when used in oncological and antimicrobial applications. Frontiers in Bioengineering and Biotechnology. October 2022.
Link to publication - Placental SCs Efficacy in a Preclinical Kidney Injury Model. Tissue Engineering. April 2022. Link to publication
- Perinatal SCs Efficacy in the Management of Preclinical Acute Kidney Injury. XV Baltic Nephrology Conference “UpToDate in Nephrology, Dialysis and Kidney Transplantation”. December 2020. Link to publication
- Placenta derived SCs for Acute Kidney Injury treatment in a xenogeneic preclinical model. Cytotherapy. May 2020. Link to publication
- Comparison of muscle-derived SCs/ progenitor cells and bone marrow mesenchymal SCs for the treatment of acute kidney injury. The 7th International Pharmaceutical Conference "Science and Practice 2016". June 2016. Link to publication
- Skeletal muscle-derived SCs/progenitor cells: A potential strategy for the treatment of acute kidney injury. Stem Cells International. March 2016. Link to publication
- Skeletal muscle-derived SCs/progenitor cells: a potential strategy for the treatment of acute kidney injury. The 6th International Pharmaceutical Conference "Science and Practice 2015". November 2015. Link to publication
- Development of experimental nephrotoxicity model in vivo and assessment of its applicability for SC research. 10th EACPT Summer School 2013. Link to publication
- Human Placental Mesenchymal SCs and Derived Extracellular Vesicles Ameliorate Lung Injury in Acute Respiratory Distress Syndrome Murine Model. Cells. November 2023. Link to publication
- Allogenic mesenchymal stromal cells and their extracellular vesicles modulate inflammation via cytotoxic and regulatory T lymphocyte populations: A pilot in-vitro study. International Seminar "Clinical Application of SCs in Kidney Transplantation and Nephrology". October 2023. Link to publication
- Immunomodulatory Effect of Mesenchymal SCs in Hidradenitis Suppurativa Patients Peripheral Blood Mononuclear Cells: Experimental Pilot Study. 32nd European Academy of Dermatology and Venereology (EADV) Congress, October 2023. Link to publication
- Perinatal SCs efficacy in the prevention of acute kidney injury progression to chronic kidney injury: Preclinical model. International Seminar "Clinical Application of Stem Cells in Kidney Transplantation and Nephrology". October 2023. Link to publication
